$98.14
0.79% yesterday
Nasdaq, Nov 04, 10:16 pm CET
ISIN
US40131M1099
Symbol
GH

Guardant Health, Inc. Stock price

$98.14
+34.76 54.84% 1M
+54.09 122.79% 6M
+67.59 221.24% YTD
+74.54 315.85% 1Y
+50.87 107.62% 3Y
-15.26 13.46% 5Y
+65.94 204.78% 10Y
+65.94 204.78% 20Y
Nasdaq, Closing price Tue, Nov 04 2025
-0.78 0.79%

New AI Insights on Guardant Health, Inc. Insights AI Insights on Guardant Health, Inc.

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$12.4b
Enterprise Value
$12.9b
Net debt
$534.6m
Cash
$580.0m
Shares outstanding
125.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
13.7 | 13.0
EV/Sales
14.3 | 13.6
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-9.4%
Return on Equity
312.5%
ROCE
-41.7%
ROIC
-69.1%
Debt/Equity
-3.1
Financials (TTM | estimate)
Revenue
$902.6m | $948.1m
EBITDA
$-393.6m | $-226.7m
EBIT
$-433.7m | $-389.1m
Net Income
$-398.8m | $-396.5m
Free Cash Flow
$-262.2m
Growth (TTM | estimate)
Revenue
30.4% | 28.3%
EBITDA
18.0% | 43.5%
EBIT
17.0% | 12.3%
Net Income
22.2% | 9.1%
Free Cash Flow
4.4%
Margin (TTM | estimate)
Gross
63.8%
EBITDA
-43.6% | -23.9%
EBIT
-48.1%
Net
-44.2% | -41.8%
Free Cash Flow
-29.1%
More
EPS
$-3.2
FCF per Share
$-2.1
Short interest
7.0%
Employees
2k
Rev per Employee
$370.0k
Show more

Is Guardant Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.

Guardant Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a Guardant Health, Inc. forecast:

30x Buy
91%
3x Hold
9%

Analyst Opinions

33 Analysts have issued a Guardant Health, Inc. forecast:

Buy
91%
Hold
9%

Financial data from Guardant Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
903 903
30% 30%
100%
- Direct Costs 327 327
19% 19%
36%
575 575
38% 38%
64%
- Selling and Administrative Expenses 658 658
30% 30%
73%
- Research and Development Expense 359 359
4% 4%
40%
-394 -394
18% 18%
-44%
- Depreciation and Amortization 40 40
6% 6%
4%
EBIT (Operating Income) EBIT -434 -434
17% 17%
-48%
Net Profit -399 -399
22% 22%
-44%

In millions USD.

Don't miss a Thing! We will send you all news about Guardant Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Guardant Health, Inc. Stock News

Neutral
Business Wire
about 10 hours ago
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the commencement of an underwritten public offering of $250.0 million of shares of Guardant Health's common stock (the “common stock offering”). Guardant Health also intends to grant the underwriters a 30-day option to purchase up to an additional $37...
Neutral
Business Wire
about 10 hours ago
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced its intention to offer $300.0 million aggregate principal amount of convertible senior notes due 2033 (the “notes”) in a private offering (the “convertible notes offering”) to persons reasonably believed to be qualified institutional buyers pursuant t...
Positive
Seeking Alpha
5 days ago
Guardant Health, Inc.'s Shield ADLT reimbursement, Quest, and guidance raise show good adoption momentum. These positives keep me bullish on GH stock. Their oncology business remains the revenue anchor. Biopharma & Data also came in with good margins and provided some diversification. GH's recent Q3 report showed growing revenues, more Shield tests, and, ex-Screening, they became cash flow posi...
More Guardant Health, Inc. News

Company Profile

Guardant Health, Inc. is a precision oncology company, which engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Redwood City, CA.

Head office United States
CEO Helmy Eltoukhy
Employees 2,010
Founded 2012
Website guardanthealth.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today